TCS, Hindustan Unilever and Cochin Shipyard to see some action today

19 Feb 2026 Evaluate

Tata Consultancy Services (TCS) and OpenAI have entered into a multi-dimensional strategic partnership, that will drive AI-powered innovation across enterprise, consumer, and social sectors. This partnership spans multiple high-impact areas, including powering AI-led innovation across Tata Group companies, joint efforts to drive AI transformation across industries globally, and setting up AI infrastructure.

Hindustan Unilever has received Board’s approval for the proposed investment of around Rs 2,000 crore over a period of two years to expand manufacturing capacity in fast-growing premium categories across Beauty & Wellbeing and Home Care. This investment will be done over a period of two years across multiple locations. The proposed investment is in line with the company’s strategy of focusing on fewer, bigger bets and strengthening its presence in high-growth demand spaces, including premium Skin care and Hair Care and Personal Care & Home Care liquids.

Cochin Shipyard has bagged a Mega order (above Rs 2000 crore) from a prominent European Client for the design and construction of six feeder container vessels, each with a capacity of about 1,700 TEU and powered by liquefied natural gas (LNG). A Letter of Intent (LOI) in this regard was signed on October 14, 2025. A formal shipbuilding contract detailing the techno?commercial terms will be signed in due course.

Dr. Reddy’s Laboratories has entered into a definitive agreement with Mercury Pharma Group (MPGL), a UK-headquartered specialty pharmaceutical company. Under the terms of the agreement, the company has acquired the trademarks, Progynova and CycloProgynova, and related assets in India. The acquisition strengthens the company’s Gynecology Portfolio in India through its foray into the Hormone Replacement Therapy segment.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Bosentan tablets, oral suspension, 32 mg (USRLD: Tracleer Tablets for Oral Suspension, 32 mg). Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension (PAH), specifically to improve exercise ability and reduce clinical worsening in children (aged 3 years and older) with idiopathic or congenital PAH. It is a dual endothelin receptor antagonist that lowers high blood pressure in the lungs, typically administered based on body weight. Bosentan 32 mg tablets will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

Pace Digitek’s material subsidiary -- M/s Lineage Power has received a purchase order worth $1,346,210 from Yaqin Chem to supply Mobile Battery Energy Storage System (BESS) on Gooseneck Trailer (200 KW-1200 KWH Battery) and Mobile BESS on Gooseneck Trailer (200 KW-2500 KWH Battery). The order is to be executed by April 2026.

Karbonsteel Engineering has won two major domestic orders aggregating Rs 51.96 crore from leading infrastructure and engineering companies. The contracts involve the manufacturing and supply of MS painted fabricated structures and building structural components. The orders are scheduled for completion by May 31, 2026. Pursuant to this development, the company’s total confirmed order book stands at around Rs 320 crore, providing strong execution visibility for the upcoming quarters.

TCS, Hindustan Unilever and Cochin Shipyard to see some action today

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.